China Medical System Holdings Limited (CMS or the Group) is pleased to announce that its subsidiary, Dermavon Holdings Limited (Dermavon,…
Browsing: Clinical Trials
Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for the conversion of acute…
– Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue…
Hengrui Pharma (“Hengrui” or “the Company”) today announced its financial results for the first half of 2026. During the reporting…
Everest Medicines (HKG: 01952) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth…
OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices…
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for…
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the…
HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM)…
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global The sixth Asia Summit on Global…
China Medical System Holdings Limited (CMS or the Group) is pleased to announce that, the Group through its wholly-owned subsidiary…
China Medical System Holdings Limited (the Group or CMS) is pleased to announce that the New Drug Application (NDA) in…
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual…
Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in…
Across the landscape of global biotech companies, the appointment of a senior executive often serves as a “barometer”—offering insights into…
On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its…
CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by…
Essex Bio-Technology Limited (EssexBio or the Company; HKG: 1061) today announces its successful participation in the 41st Asia-Pacific Academy of…
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine OBI Pharma (4174.TWO) announced that it…
PromiCell, Inc. (the Company), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients,…